Skip to main content
. 2016 Jun 13;11(1):87–92. doi: 10.5009/gnl15549

Table 3.

Changes in EORTC STO-22 Scores

EORTC-STO 22 Baseline 7 day 3 mo 6 mo p-value* p-value p-value p-value§
Body image 8.61±18.15 10.28±19.86 8.48±17.63 5.67±14.99 <0.001 0.0272 0.83 0.0052
Dysphagia 6.38±11.68 6.85±12.51 4.03±7.61 3.45±6.56 <0.001 0.2608 <0.001 <0.001
Pain 11.05±13.68 17.63±16.70 9.74±11.13 8.43±11.26 <0.001 <0.001 0.0513 0.0001
Reflux 10.32±13.94 8.78±14.19 7.01±11.05 6.21±11.59 <0.001 0.0182 <0.001 <0.001
Eating 5.04±9.51 7.05±12.72 3.42±8.53 2.77±7.44 <0.001 <0.001 0.0007 <0.001
Anxiety 21.14±20.34 25.96±18.36 20.38±15.77 17.92±15.14 <0.001 <0.001 0.725 0.0007
Dry mouth 17.58±23.27 17.97±22.73 16.09±21.27 14.70±20.69 <0.001 0.7601 0.2532 0.0158
Taste 4.73±13.26 5.78±15.77 3.16±11.06 1.99±9.11 <0.001 0.1566 0.0137 <0.001
Hair loss 34.77±29.33 30.87±24.31 29.30±21.72 29.73±23.30 <0.001 0.0873 0.029 0.1201

Data are presented as mean±SD.

EORTC STO-22, European Organization for Research and Treatment of Cancer gastric cancer-specific questionnaire.

*

p-value for the time effect using the generalized estimating equation (GEE) method;

p-value for comparison between screening and 7 days using the GEE method;

p-value for comparison between screening and 3 months using the GEE method;

§

p-value for comparison between screening and 6 months using the GEE method.